Jazz Pharmaceuticals plc (JAZZ) compared with its closest peers (ALNY, BMRN, UTHR, SRPT, PTCT): P/E 16.9 vs industry 17.2. Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Alnylam Pharmaceuticals, BioMarin Pharmaceutical, United Therapeutics, Sarepta Therapeutics, PTC Therapeutics, Phibro Animal Health, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Indivior Pharmaceuticals and Lakefront Biotherapeutics share Jazz Pharmaceuticals's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Alnylam Pharmaceuticals, Inc. (ALNY) | $35.68B | 66.6 |
| BioMarin Pharmaceutical Inc. (BMRN) | $12.97B | 177.8 |
| United Therapeutics Corporation (UTHR) | $20.89B | 15.9 |
| Sarepta Therapeutics, Inc. (SRPT) | $2.45B | 37.7 |
| PTC Therapeutics, Inc. (PTCT) | $5.99B | 9.8 |
| Phibro Animal Health Corporation (PAHC) | $1.64B | 16.4 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $141.32B | 32.1 |
| Regeneron Pharmaceuticals, Inc. (REGN) | $90.33B | 20.9 |
| Indivior Pharmaceuticals Inc (INDV) | $4.13B | 11.6 |
| Lakefront Biotherapeutics NV (LKFT) | $1.90B | 5.9 |
| Stock P/E | 16.9 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | -21.6% |
| vs Industry | -1.7% |
JAZZ overview · JAZZ earnings · JAZZ financials · JAZZ KPIs · JAZZ documents · JAZZ ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.